NLX-P101, an adeno-associated virus gene therapy encoding glutamic acid decarboxylase, for the potential treatment of Parkinson's disease

Current Opinion in Investigational Drugs

Volumn 11, Issue 7, 2010, Pages 813-822

  Diaz Nido, Javier ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMATE DECARBOXYLASE; NLX P101; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG FATALITY; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; GENE TRANSFER; HUMAN; INJECTION SITE BLEEDING; INJECTION SITE EDEMA; NEUROLOGICAL COMPLICATION; NONHUMAN; PARKINSON DISEASE; REVIEW; ANIMAL; DEPENDOPARVOVIRUS; ENZYMOLOGY; GENE THERAPY; GENE VECTOR; GENETICS; PATENT; PROCEDURES; SUBTHALAMIC NUCLEUS;

ANIMALS; DEPENDOVIRUS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; GLUTAMATE DECARBOXYLASE; HUMANS; PARKINSON DISEASE; PATENTS AS TOPIC; SUBTHALAMIC NUCLEUS;

EID: 77954116887     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. 380153 Novel tools for production and purification of recombinant adeno-associated virus vectors. Grimm D, Kern A, Rittner K, Kleinschmidt JA Hum GeNe THeR 1998 9 18 2745-2760
2. 398637 Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. Clark KR, Liu XL, McGrath JP, Johnson PR Hum GeNe THeR 1999 10 6 1031-1039
3. 394675 Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu YP, Leventhal L, McBride J, Chen EY, Palfi S, Roitberg BZ, Brown WD et al SCIeNCe 2000 290 5492 767-773
4. 466468 Subthalamic GAD gene therapy in a Parkinson's disease rat model. Luo J, Kaplitt MG, Fitzsimons HL, Zuzga DS, Liu Y, Oshinsky ML, During MJ SCIeNCe 2002 298 5592 425-429
5. 597105 Phase I study of AAV-GAD gene therapy of the subthalamic nucleus for Parkinson's disease. Kaplitt MG, Eidelberg D, Feigin A, Mattis P, Zimmerman R, Heier L, Kuo YH, Strybing K, Lozano A, During M Am ASSOC NeuROL SuRG ANN meeT 2005 Abs 24611
6. 682447 Neurologix signs strategic license agreement for component of its Parkinson's gene therapy product. Neurologix Inc PReSS ReLeASe 2006 August 07
7. 689035 Striatal delivery of rAAV-hAADC to rats with preexisting immunity to AAV. Sanftner LM, Suzuki BM, Doroudchi MM, Feng L, McClelland A, Forsayeth JR, Cunningham J mOL THeR 2004 9 3 403-409
8. 733283 Humoral immune response in a clinical trial of AAV-GAD gene therapy for Parkinson's disease. Fitzsimons HL, Bland R, Kaplitt MG, Feigin AS, Eidelberg D, During M ABSTR SOC NeuROSCI 2006 36 Abs 470.15/LL41
9. 822561 Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: An open label, phase I trial. Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, Strybing K, Eidelberg D, During MJ LANCeT 2007 369 9579 2097-2105
10. 860814 Neurologix gene therapy approach to Parkinson's disease granted fast track designation from FDA. Neurologix Inc PReSS ReLeASe 2007 December 13
11. 936307 Neurologix initiates recruitment for phase 2 Parkinson's disease trial. Neurologix Inc PReSS ReLeASe 2008 August 19
12. 966722 Ceregene announces clinical data from phase 2 clinical trial of CERE-120 for Parkinson's disease. Ceregene Inc PReSS ReLeASe 2008 November 26
13. 983895 Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Feigin A, Kaplitt MG, Tang C, Lin T, Mattis P, Dhawan V, During MJ, Eidelberg D PROC NATL ACAD SCI uSA 2007 104 49 19559-19564
14. 983896 Subthalamic glutamic acid decarboxylase gene therapy: Changes in motor function and cortical metabolism. Emborg ME, Carbon M, Holden JE, During MJ, Ma YL, Tang CK, Moirano J, Fitzsimons H, Roitberg BZ, Tuccar E, Roberts A et al J CeReB BLOOD FLOW meTAB 2007 27 3 501-509
15. 983897 Safety and efficacy of AAV-GAD gene therapy in human Parkinson's disease. Kaplitt MG, During MJ, Feigin A, Tang C, Eidelberg D STeReOTACT FuNCT NeuROSuRG 2007 85 1 22-23
16. 983898 Gene therapy for Parkinson's disease with AAV-GAD: Interim FDG-PET results. Feigin A, Tang C, Ma Y, Dhawan V, During M, Kaplitt M, Eidelberg D NeuROLOGY 2006 66 5 Suppl 2 Abs P01.146
17. 1012853 Ceregene presents additional clinical data from phase 2 trial of CERE-120 for Parkinson's disease. Ceregene Inc PReSS ReLeASe 2009 May 27
18. 1031843 Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: An open-label, phase I trial. Marks WJ, Ostrem JL, Verhagen L, Starr PA, Larson PS, Bakay RAE, Taylor R, Cahn-Weiner DA, Stoessl AJ, Olanow CW, Bartus RT LANCeT NeuROLOGY 2008 7 5 400-408
19. 1031941 Issues regarding gene therapy products for Parkinson's disease: The development of CERE-120 (AAV-NTN) as one reference point. Bartus RT, Herzog CD, Bishop K, Ostrove JM, Tuszynski M, Kordower JH, Gasmi M PARKINSONISm ReLAT DISORD 2007 13 Suppl 3 S469-S477
20. 1061861 Neurologix completes all surgical procedures in its clinical trial for Parkinson's disease. Neurologix Inc PReSS ReLeASe 2009 December 03
21. 1071471 Viral vectors for in vivo gene transfer in Parkinson's disease: Properties and clinical grade production. Mandel RJ, Burger C, Snyder RO eXP NeuROL 2008 209 1 58-71
22. 1072378 Gene therapy for Parkinson's disease with AAV-GAD: An open-label, dose escalation, safety-tolerability trial. Feigin A, Kaplitt M, During M, Strybing K, Cox M, Dhawan V, Eidelberg D mOV DISORD 2005 20 9 1236
23. 1072379 Gene therapy for Parkinson's disease with subthalamic nucleus AAV-GAD: FDG-PET results. Feigin A, Tang C, During M, Kaplitt M, Eidelberg D mOV DISORD 2006 21 9 1543-1544
24. 1072389 Improvements in clinical and radiographic outcomes in a phase I study of AAV-GAD gene therapy for Parkinson's disease. Kaplitt MG, Eidelberg D, Feigin A, Fitzimmons H, Lawlor P, Strybing K, Cox M, Tang C, Bland R Am SOC GeNe THeR 2006 9 Abs 727
25. 1100198 Biodistribution and safety assessment of AAV2-GAD following intrasubthalamic injection in the rat. Fitzsimons HL, Riban V, Bland RJ, Wendelken JL, Sapan CV, During MJ J GeNe meD 2010 12 4 385-398
26. 1100925 Parkinson's disease. Lees AJ, Hardy J, Revesz T LANCeT 2009 373 9680 2055-2066
27. 1100931 Etiopathogenesis and treatment of Parkinson's disease. Gallagher DA, Schapira AHV CuRR TOP meD CHem 2009 9 10 860-868
28. 1100932 Perspectives on recent advances in the understanding and treatment of Parkinson's disease. Schapira AH, Agid Y, Barone P, Jenner P, Lemke MR, Poewe W, Rascol O, Reichmann H, Tolosa E euR J NeuROL 2009 16 10 1090-1099
29. 1100933 Neuropathology of non-motor features of Parkinson's disease. Dickson DW, Fujishiro H, Orr C, DelleDonne A, Josephs KA, Frigerio R, Burnett M, Parisi JE, Klos KJ, Ahlskog JE PARKINSONISm ReLAT DISORD 2009 15 Suppl 3 S1-S5
30. 1100934 Non-motor symptoms of Parkinson's disease: Dopaminergic pathophysiology and treatment. Chaudhuri KR, Schapira AHV LANCeT NeuROLOGY 2009 8 5 464-474
31. 1100938 The origin of motor fluctuations in Parkinson's disease: Importance of dopaminergic innervation and basal ganglia circuits. Obeso JA, Rodriguez-Oroz M, Marin C, Alonso F, Zamarbide I, Lanciego JL, Rodriguez-Diaz M NeuROLOGY 2004 62 1 S17-S30
32. 1100939 The basal ganglia in Parkinson's disease: Current concepts and unexplained observations. Obeso JA, Marin C, Rodriguez-Oroz C, Blesa J, Benitez-Temino B, Mena-Segovia J, Rodriguez M, Olanow CW ANN NeuROL 2008 64 6 S30-S46
33. 1100941 Update on models of basal ganglia function and dysfunction. DeLong M, Wichmann T PARKINSONISm ReLAT DISORD 2009 15 Suppl 3 S237-S240
34. 1100942 Challenges in Parkinson's disease: Restoration of the nigrostriatal dopamine system is not enough. Lang AE, Obeso JA LANCeT NeuROLOGY 2004 3 5 309-316
35. 1100946 Parkinson's disease: Primacy of age as a risk factor for mitochondrial dysfunction. Van Itallie TB meTAB CLIN eXP 2008 57 10 S50-S55
36. 1100954 Epidemiologic studies of environmental exposures in Parkinson's disease. Elbaz A, Tranchant C J NeuROL SCI 2007 262 1-2 37-44
37. 1100955 Nongenetic causes of Parkinson's disease. Chade AR, Kasten M, Tanner CM J NeuRAL TRANSm SuPPL 2006 70 147-151
38. 1100956 Pathogenesis of familial Parkinson's disease: New insights based on monogenic forms of Parkinson's disease. Hatano T, Kubo S, Sato S, Hattori N J NeuROCHem 2009 111 5 1075-1093
39. 1100957 Parkinson's disease: From monogenic forms to genetic susceptibility factors. Lesage S, Brice A Hum mOL GeNeT 2009 18 R48-R59
40. 1100958 Parkinson's disease: Exit toxins, enter genetics. Westerlund M, Hoffer B, Olson L PROG NeuROBIOL 2010 90 2 146-156
41. 1100959 The genetics of Parkinson's syndromes: A critical review. Hardy J, Lewis P, Revesz T, Lees A, Paisan-Ruiz C CuRR OPIN GeNeT DeV 2009 19 3 254-265
42. 1100960 Update on the pathogenesis of Parkinson's disease. Schulz JB J NeuROL 2008 255 Suppl 5 3-7
43. 1100963 What causes cell death in Parkinson's disease? Gupta A, Dawson VL, Dawson TM ANN NeuROL 2008 64 6 3-S15
44. 1100964 Glutamate, excitotoxicity, and programmed cell death in Parkinson's disease. Caudle WM, Zhang J eXP NeuROL 2009 220 2 230-233
45. 1100966 Functional models of Parkinson's disease: A valuable tool in the development of novel therapies. Jenner P ANN NeuROL 2008 64 6 S16-S29
46. 1100967 Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Schober A CeLL TISSue ReS 2004 318 1 215-224
47. 1100969 Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson's disease. Meredith GE, Totterdell S, Beales M, Meshul CK eXP NeuROL 2009 219 1 334-340
48. 1100970 Differences between subacute and chronic MPTP mice models: Investigation of dopaminergic neuronal degeneration and α-synuclein inclusions. Gibrat C, Saint-Pierre M, Bousquet M, Levesque D, Rouillard C, Cicchetti F J NeuROCHem 2009 109 5 1469-1482
49. 1100972 Environmental toxins and Parkinson's disease: What have we learned from pesticide-induced animal models? Cicchetti F, Drouin-Ouellet J, Gross RE TReNDS PHARmACOL SCI 2009 30 9 475-483
50. 1100973 A highly reproducible rotenone model of Parkinson's disease. Cannon JR, Tapias V, Na HM, Honick AS, Drolet RE, Greenamyre JT NeuROBIOL DIS 2009 34 2 279-290
51. 1100974 Genetic models of Parkinson's disease. Lim KL, Ng CH BIOCHIm BIOPHYS ACTA mOL BASIS DIS 2009 1792 7 604-615
52. 1100975 Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant α-synuclein. Lu XH, Fleming SM, Meurers B, Ackerson LC, Mortazavi F, Lo V, Hernandez D, Sulzer D, Jackson GR, Maidment NT, Chesselet MF et al J NeuROSCI 2009 29 7 1962-1976
53. R1441G BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Li YP, Liu WC, Oo TF, Wang L, Tang Y, Jackson-Lewis V, Zhou C, Geghman K, Bogdanov M, Przedborski S, Beal MF et al NAT NeuROSCI 2009 12 7 826-828
54. 1100995 Current strategies in the treatment of Parkinson's disease and a personalized approach to management. Diaz NL, Waters CH eXPeRT ReV NeuROTHeR 2009 9 12 1781-1789
55. 1100999 Surgery insight: Deep brain stimulation for movement disorders. Anderson WS, Lenz FA NAT CLIN PRACT NeuROL 2006 2 6 310-320
56. 1101000 Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease. Benabid AL, Chabardes S, Mitrofanis J, Pollak P LANCeT NeuROLOGY 2009 8 1 67-81
57. 1101001 Basal ganglia physiology and deep brain stimulation. Lozano AM, Snyder BJ, Hamani C, Hutchison WD, Dostroysky JO mOV DISORD 2010 25 3 S71-S75
58. 1101003 Long-term hardware-related complications of deep brain stimulation. Oh MY, Abosch A, Kim SH, Lang AE, Lozano AM NeuROSuRGeRY 2002 50 6 1268-1274
59. 1101004 Adenosine is crucial for deep brain stimulation-mediated attenuation of tremor. Bekar L, Libionka W, Tian GF, Xu QW, Torres A, Wang XH, Lovatt D, Williams E, Takano TH, Schnermann J, Bakos R et al NAT meD 2008 14 1 75-80
60. 1101005 Is deep brain stimulation neuroprotective if applied early in the course of PD? Charles PD, Gill CE, Davis TL, Konrad PE, Benabid AL NAT CLIN PRACT NeuROL 2008 4 8 424-426
61. 1101006 Dopaminergic transplantation for Parkinson's disease: Current status and future prospects. Olanow CW, Kordower JH, Lang AE, Obeso JA ANN NeuROL 2009 66 5 591-596
62. 1101007 Prospects of stem cell therapy for replacing dopamine neurons in Parkinson's disease. Lindvall O, Kokaia Z TReNDS PHARmACOL SCI 2009 30 5 260-267
63. 1101008 Propagation of host disease to grafted neurons: Accumulating evidence. Kordower JH, Brundin P eXP NeuROL 2009 220 2 224-225
64. 1101052 Dissecting the potential molecular mechanisms underlying α-synuclein cell-to-cell transfer in Parkinson's disease. Angot E, Brundin P PARKINSONISm ReLAT DISORD 2009 15 Suppl 3 S143-S147
65. 1101054 Viral vectors for neurotrophic factor delivery: A gene therapy approach for neurodegenerative diseases of the CNS. Lim ST, Airavaara M, Harvey BK PHARmACOL ReS 2010 61 1 14-26
66. 1101055 Gene therapy for Parkinson's disease. Bjorklund T, Kordower JH mOV DISORD 2010 25 3 S161-S173
67. 1101056 Scientific rationale for the development of gene therapy strategies for Parkinson's disease. Bjorklund T, Kirik D BIOCHIm BIOPHYS ACTA mOL BASIS DIS 2009 1792 7 703-713
68. 1101057 Preclinical development of gene therapy for Parkinson's disease. Porras G, Bezard E eXP NeuROL 2008 209 1 72-81
69. 1101058 Safety and tolerability of putaminal AADC gene therapy for Parkinson's disease. Christine CW, Starr PA, Larson PS, Eberling JL, Jagust WJ, Hawkins RA, VanBrocklin HF, Wright JF, Bankiewicz KS, Aminoff MJ NeuROLOGY 2009 73 20 1662-1669
70. 1101059 Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Jarraya B, Boulet S, Ralph GS, Jan C, Bonvento G, Azzouz M, Miskin JE, Shin M, Delzescaux T, Drouot X, Herard AS et al SCI TRANSLATIONAL meD 2009 1 2 2ra4
71. 1101060 Gene therapy for neurological disorders: Challenges and future prospects for the use of growth factors for the treatment of Parkinson's disease. Manfredsson FP, Okun MS, Mandel RJ CuRR GeNe THeR 2009 9 5 375-388
72. 1101061 Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in Parkinsonian Rhesus monkeys. Eberling JL, Kells AP, Pivirotto P, Beyer J, Bringas J, Federoff HJ, Forsayeth J, Bankiewicz KS Hum GeNe THeR 2009 20 5 511-518
73. 1101086 Improvement in human basal ganglia metabolism in an open-label, phase I study of gene therapy for Parkinson's disease. Kaplitt MG, Feigin A, During MJ, Tang C, Strybing K, Cox M, Eidelberg D Am ASSOC NeuROL SuRG ANN meeT 2006 Abs 36847
74. 1101087 Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and Parkinsonian Rhesus monkeys. Su X, Kells AP, Huang EJ, Lee HS, Hadaczek P, Beyer J, Bringas J, Pivirotto P, Penticuff J, Eberling J, Federoff HJ et al Hum GeNe THeR 2009 20 12 1627-1640
75. 1101088 Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Kordower JH, Palfi S, Chen EY, Ma SY, Sendera T, Cochran EJ, Mufson EJ, Penn R, Goetz CG, Comella CD ANN NeuROL 1999 46 3 419-424
76. 1101090 Subthalamic GAD gene transfer in Parkinson's disease patients who are candidates for deep brain stimulation. During MJ, Kaplitt MG, Stern MB, Eidelberg D Hum GeNe THeR 2001 12 12 1589-1591
77. 1101091 Enhanced expression of glutamate decarboxylase 65 improves symptoms of rat Parkinsonian models. Lee B, Lee H, Nam YR, Oh JH, Cho YH, Chang JW GeNe THeR 2005 12 15 1215-1222
78. 1101097 Anti-apoptotic gene therapy in Parkinson's disease. Schulz JB J NeuRAL TRANSm SuPPL 2006 70 467-476
79. 1101098 Gazing into the future: Parkinson's disease gene therapeutics to modify natural history. Maguire-Zeiss KA, Mhyre TR, Federoff HJ eXP NeuROL 2008 209 1 101-113
80. 1101163 Two isoforms of glutamate decarboxylase: Why? Soghomonian JJ, Martin DL TReNDS PHARmACOL SCI 1998 19 12 500-505
81. 1101219 Network modulation by the subthalamic nucleus in the treatment of Parkinson's disease. Trost M, Su S, Su P, Yen RF, Tseng HM, Barnes A, Ma YL, Eidelberg D NeuROImAGe 2006 31 1 301-307
82. 1101227 Metabolic networks for assessment of therapy and diagnosis in Parkinson's disease. Hirano S, Eckert T, Flanagan T, Eidelberg D mOV DISORD 2009 24 14 S725-S731
83. 1101245 Progress and prospects: Immunobiology of gene therapy for neurodegenerative disease: Prospects and risks. McMenamin MM, Wood MJA GeNe THeR 2010 17 4 448-458
84. 1101247 Striatal re-administration of rAAV vectors reveals an immune response against AAV2 capsids that can be circumvented. Peden CS, Manfredsson FP, Reimsnider SK, Poirier AE, Burger C, Muzyczka N, Mandel RJ mOL THeR 2009 17 3 524-537
85. 1101250 Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal system. McFarland NR, Lee JS, Hyman BT, McLean PJ J NeuROCHem 2009 109 3 838-845
86. 1105233 Chapter 58: Psychiatric and pain disorders. Sheenan J, Pouratian N, Sansur C PRINCIPLeS AND PRACTICe OF STeReOTACTIC RADIOSuRGeRY (eDS: CHIN L, ReGINe WF) 2008 Springer Publishing, New York, NY, USA 1st Edition 563-573